Efficacy and safety of 6.25 mg t.i.d. feverfew CO2-extract (MIG-99) in migraine prevention - A randomized, double-blind, multicentre, placebo-controlled study

Cephalalgia

Volumn 25, Issue 11, 2005, Pages 1031-1041

  Diener, Hans Christoph ^a,e   Pfaffenrath, V ^b   Schnitker, J ^c   Friede, M ^d   Henneicke Von Zepelin, H H ^d  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Institut für Angewandte Statistik ^*  (Germany)

^c Institut für Angewandte Statistik IAS   (Germany)

^d Schaper & Brummer GmbH & Co KG   (Germany)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

Clinical Study; Efficacy; Feverfew; Safety; Tanacetum parthenium

Indexed keywords

TANACETUM PARTHENIUM EXTRACT;

ABDOMINAL PAIN; ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GYNECOLOGIC DISEASE; HEARING DISORDER; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; MENTAL DISEASE; METABOLIC DISORDER; MIGRAINE; MULTICENTER STUDY; MUSCULOSKELETAL DISEASE; NEOPLASM; NUTRITIONAL DISORDER; PERIPHERAL NEUROPATHY; PHYSICAL EXAMINATION; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; URINARY TRACT DISEASE; VESTIBULAR DISORDER;

ADOLESCENT; ADULT; CARBON DIOXIDE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PHYTOTHERAPY; PLANT EXTRACTS; TANACETUM PARTHENIUM;

EID: 27444444838     PISSN: 03331024     EISSN: 14682982     Source Type: Journal    
DOI: 10.1111/j.1468-2982.2005.00950.x     Document Type: Article

References (28)

1. Linde K. Gibt es Evidenz für die Wirksamkeit komplementä rmedizinischer Therapien für die Migräne-Prophylaxe? Bundesgesundheitsbl - Gesundheitsforsch - Gesundheitsschutz 2002; 45:425-9.
2. Kulkarni SK, Jain NK. Feverfew: ancient remedy for multiple disorders. Drugs Fut 1999; 24:1339-43.
3. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. BMJ 1985; 291:569-73.
4. Murphy JJ, Heptinstall S, Mitchell JRA. Randomised double-blind placebo-controlled trial of feverfew in migraine prevention. Lancet 1988; 2(8604):189-92.
5. Palevitch D, Earon G, Carasso R. Feverfew (Tanacetum parthenium) as a prophylactic treatment for migraine: a double-blind placebo-controlled study. Phythother Res 1997; 11:508-11.
6. de Weerdt CJ, Bootsma HPR, Hendriks H. Herbal medicines in migraine prevention. Phytomedicine 1996; 3:225-30.
7. Ernst E, Pittler MH. The efficacy and safety of feverfew (Tanacetum parthenium L.): an update of a systematic review. Public Health Nutr 2000; 3:509-14.
8. International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine, second edition. Cephalalgia 2000; 20:765-86.
9. Willigmann I, Freudenstein J. Production of a stable fever-few (Tanacetum parthenium) extract as an active substance for a pharmaceutical product. Poster Symposium. Vienna: Society for Medicinal Plant Research, 1998.
10. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999; 56:125-38.
11. ESCOP European Scientific Cooperative on Phytotherapy. Tanaceti parthenii herba, feverfew. ESCOP Monographs, 2nd edn. Stuttgart, New York: Thieme, 2003:492-8.
12. Diener H-C, Limmroth V. Advances in pharmacological treatment of migraine. Expert Opin Invest Drugs 2001; 10:1831-45.
13. Goadsby PJ, Lipton RB, Ferrari MD. Migraine - current understanding and treatment. N Engl J Med 2002; 346:257-70.
14. Pfaffenrath V, Diener HC, Fischer M, Friede M, Henneicke-von Zepelin HH. The efficacy and safety of Tanacetum parthenium (feverfew) in migraine prophylaxis - a doubleblind, multicentre, randomized placebo-controlled dose-response study. Cephalalgia 2002; 22:523-32.
15. Lehmacher W, Wassmer G. Adaptive sample size calculations in group sequential trials. Biometrics 1999; 55:1286-90.
16. Vogler BK, Pittler MH, Ernst E. Feverfew as a preventive treatment for migraine: a systematic review. Cephalalgia 1998; 18:704-8.
17. Bousser MG, Baron JC. Drug trials in migraine. Neuroepidemiology 1987; 6:228-33.
18. Cady R, Dodock DW. Diagnosis and treatment of migraine. Mayo Clin Proc 2002; 77:255-61.
19. Holroyd KA, Penzien DB, Cordingley GE. Propranolol in the management of recurrent migraine: a metaanalytic review. Headache 1991; 31:333-40.
20. Silberstein SD. Divalproex sodium in headache: literature review and clinical guidelines. Headache 1996; 36:547-55.
21. Brandes J, Saper J, Diamond M, Couch J, Lewis D, Schmitt J et al. Topiramate for migraine prevention: a randomized controlled trial. JAMA 2004; 291:965-73.
22. Silberstein SD, Goadsby PJ. Migraine: preventive treatment. Cephalalgia 2002; 22:491-512.
23. Silberstein SD, Neto W, Schmitt J, Jacobs D, Topiramate in migraine prevention. Results of a large controlled trial. Arch Neurol 2004; 61:490-5.
24. Mauskop A. Alternative therapies in headache. Med Clin North Am 2001; 85:1077-84.
25. Chavez MI, Chavez PI. Feverfew. Hosp Pharm 1999; 34:436-61.
26. Paulsen E, Christensen LP, Andersen KE. Do monoterpenes released from feverfew (Tanacetum parthenium) plants cause airborne Compositae dermatitis? Contact Derm 2002; 47:14-8.
27. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review). Neurology 2000; 55:754-63.
28. Linde K, Rossnagel K. Propranolol for migraine prophylaxis. Cochraine Database Syst Rev 2004; 2:CD003225.